LEHIGH UNIVERSITY
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1865-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.lehigh.edu
Cabaletta Bio Announces Positive Clinical Updates for CABA-201 in Autoimmune Diseases
• Cabaletta Bio reported clinical data from RESET-Myositis™, RESET-SLE™, and initial data from RESET-SSc™ trials at ACR Convergence 2024, showcasing CABA-201's potential in autoimmune disease treatment.
• Sixteen patients have been enrolled, with ten dosed across the RESET™ clinical development program, and 40 U.S. clinical sites are actively recruiting patients for CABA-201 trials.
• Cabaletta anticipates a meeting with the FDA in 2025 to discuss potential registrational program designs for CABA-201, pending data outcomes.
• EMA has authorized clinical trials for CABA-201 in Europe for lupus, expanding the clinical development program internationally.
© Copyright 2025. All Rights Reserved by MedPath